# Eli Lilly (LLY) and Novo Nordisk (NVO) surged Thursday morning after the US FDA proposed placing a significant restriction on the ability of pharmacies to make compounded versions of GLP-1.

*biotech · news · 2026-04-30 · Seeking Alpha*

## Key points

- The US FDA proposed significant restrictions on pharmacies compounding GLP-1 weight loss drugs.
- Eli Lilly and Novo Nordisk stocks surged following the FDA's proposed compounding restrictions.
- The FDA's move directly targets pharmacies making non-branded versions of GLP-1 medications.
- These proposed FDA restrictions could further solidify the market dominance of LLY and NVO.

**Companies:** Eli Lilly and Company, Novo Nordisk
**Countries:** United States, Denmark

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4582955-lilly-novo-nordisk-gain-fda-glp-1-compounding-exclusion-proposal)

---

Canonical: https://newsio.io/n/37b86059-977a-441a-bfe2-e07a135831fc/eli-lilly-lly-and-novo-nordisk-nvo-surged-thursday-morning-after-the-us-fda-prop
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works